Drug intelligence / Profile preview

AM2250

Development stage: Preclinical
Lead developer: AMW
Modality: Small Molecules
Administration: Intravitreal, Implant

Overview

AM2250 is a preclinical-stage biodegradable intravitreal implant developed by AMW GmbH for the treatment of retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. The drug utilizes a long-acting delivery system designed to provide controlled release of the active pharmaceutical ingredient over a period of six months or longer. This sustained-release profile aims to reduce the frequency of intravitreal injections, thereby improving patient compliance and treatment outcomes in chronic ocular conditions.

Beyond the preview

Go deeper on AM2250.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM2250.

Explore the full profile